麝香通心滴丸对低血压慢性收缩性心力衰竭患者治疗效果的研究(1)
[摘要] 目的 探討麝香通心滴丸对低血压慢性收缩性心力衰竭患者治疗效果。 方法 选择我院于2017年9月～2018年12月心内科住院的低血压慢性收缩性心力衰竭患者240例，采用随机数字表法分为观察组120例与对照组120例。对照组患者采用常规治疗，观察组在对照组基础上结合麝香通心滴丸。两组疗程均为24周。比较两组治疗疗效，治疗前后收缩压和舒张压、心肌标志物、心功能、6 min步行距离(6MWT)和N末端B型钠尿肽前体(NT-proBNP)变化。 结果 观察组总有效率(91.67%)高于对照组(75.83%)(P<0.05)。两组治疗后收缩压和舒张压较治疗前升高(P<0.05);观察组治疗后收缩压和舒张压高于对照组(t=18.432、16.237，P<0.05)。两组治疗后CK、LDH、CK-MB和cTnT较治疗前降低(P<0.05);观察组治疗后CK、LDH、CK-MB和cTnT低于对照组(t=8.145、15.820、17.561、16.305，P<0.05)。两组治疗后LVEDD较治疗前降低，而LVEF较治疗前升高(P<0.05);观察组治疗后LVEDD低于对照组，而LVEF高于对照组(t=17.499、12.089，P<0.05)。两组治疗后6MWT较治疗前增加，而NT-proBNP水平较治疗前降低(P<0.05);观察组治疗后6MWT高于对照组，而NT-proBNP水平低于对照组(t=11.992、23.429，P<0.05)。 结论 麝香通心滴丸对低血压慢性收缩性心力衰竭患者治疗疗效良好，可提高血压，降低心肌标志物水平，改善患者心功能，降低NT-proBNP水平。
[关键词] 麝香通心滴丸;低血压;慢性收缩性心力衰竭;血压;心肌标志物;心功能;6 min步行距离;N末端B型钠尿肽前体
[中图分类号] R541.6;R544.2 [文献标识码] B [文章编号] 1673-9701(2020)14-0049-04
[Abstract] Objective To explore the therapeutic effect of Shexiang Tongxin drop pills in patients with chronic hypertension and systolic heart failure. Methods 240 patients with hypotension and chronic systolic heart failure who were admitted to the department of cardiology in our hospital from September 2017 and December 2018 were selected and divided into the observation group(n=120) and the control group(n=120) by using random number table method. The control group was treated with the routine method， and the observation group was given Shexiang Tongxin drop pill on the basis of the control group. Both groups were treated for 24 weeks. The therapeutic effects of the two groups were compared， and the changes in systolic and diastolic blood pressure， myocardial markers， cardiac function， 6-minute walking distance(6MWD) and N-terminal brain natriuretic peptide(NT-proBNP) were compared before and after treatment. Results The total effective rate in the observation group(91.67%) was higher than that in the control group(75.83%)(P<0.05). After treatment， the systolic and diastolic blood pressures in the two groups were higher than those before treatment(P<0.05). The systolic and diastolic blood pressures in the observation group were higher than those in the control group after treatment(t=18.432， 16.237， P<0.05). Creatine kinase(CK)， lactate dehydrogenase(LDH)， creatine kinase-MB(CK-MB) and troponin T(cTnT) in the two groups were lower than those before treatment(P<0.05). CK， LDH， CK-MB and cTnT in the observation group were lower than those in the control group after treatment(t=8.145， 15.820， 17.561， 16.305， P<0.05). After treatment， left ventricular end diastolic dimension(LVEDD) decreased and left ventricular ejection fraction(LVEF) increased in both groups(P<0.05). LVEDD was lower in the observation group than that in the control group and LVEF was higher than that in the control group after treatment(t=17.499， 12.089， P<0.05). 6MWD was higher than that before treatment in both groups， and NT-proBNP level was lower than that before treatment(P<0.05). 6MWD in observation group was higher than that in control group， and NT-proBNP level was lower than that in control group after treatment(t=11.992， 23.429， P<0.05). Conclusion Shexiang Tongxin drop pill is effective in treating patients with hypotension and chronic systolic heart failure. It can increase blood pressure， reduce myocardial marker levels， improve heart function， and reduce NT-proBNP levels., http://www.100md.com(何志鹏 吴琪 翁敏杰 唐延甜 史佩剑 陈檀琦 章顺安)
[关键词] 麝香通心滴丸;低血压;慢性收缩性心力衰竭;血压;心肌标志物;心功能;6 min步行距离;N末端B型钠尿肽前体
[中图分类号] R541.6;R544.2 [文献标识码] B [文章编号] 1673-9701(2020)14-0049-04
[Abstract] Objective To explore the therapeutic effect of Shexiang Tongxin drop pills in patients with chronic hypertension and systolic heart failure. Methods 240 patients with hypotension and chronic systolic heart failure who were admitted to the department of cardiology in our hospital from September 2017 and December 2018 were selected and divided into the observation group(n=120) and the control group(n=120) by using random number table method. The control group was treated with the routine method， and the observation group was given Shexiang Tongxin drop pill on the basis of the control group. Both groups were treated for 24 weeks. The therapeutic effects of the two groups were compared， and the changes in systolic and diastolic blood pressure， myocardial markers， cardiac function， 6-minute walking distance(6MWD) and N-terminal brain natriuretic peptide(NT-proBNP) were compared before and after treatment. Results The total effective rate in the observation group(91.67%) was higher than that in the control group(75.83%)(P<0.05). After treatment， the systolic and diastolic blood pressures in the two groups were higher than those before treatment(P<0.05). The systolic and diastolic blood pressures in the observation group were higher than those in the control group after treatment(t=18.432， 16.237， P<0.05). Creatine kinase(CK)， lactate dehydrogenase(LDH)， creatine kinase-MB(CK-MB) and troponin T(cTnT) in the two groups were lower than those before treatment(P<0.05). CK， LDH， CK-MB and cTnT in the observation group were lower than those in the control group after treatment(t=8.145， 15.820， 17.561， 16.305， P<0.05). After treatment， left ventricular end diastolic dimension(LVEDD) decreased and left ventricular ejection fraction(LVEF) increased in both groups(P<0.05). LVEDD was lower in the observation group than that in the control group and LVEF was higher than that in the control group after treatment(t=17.499， 12.089， P<0.05). 6MWD was higher than that before treatment in both groups， and NT-proBNP level was lower than that before treatment(P<0.05). 6MWD in observation group was higher than that in control group， and NT-proBNP level was lower than that in control group after treatment(t=11.992， 23.429， P<0.05). Conclusion Shexiang Tongxin drop pill is effective in treating patients with hypotension and chronic systolic heart failure. It can increase blood pressure， reduce myocardial marker levels， improve heart function， and reduce NT-proBNP levels., http://www.100md.com(何志鹏 吴琪 翁敏杰 唐延甜 史佩剑 陈檀琦 章顺安)
参见：首页 > 医疗版 > 疾病专题 > 心血管科 > 心力衰竭